TY - JOUR
T1 - HVAD to Heartmate 3 Device Exchange
T2 - A Society of Thoracic Surgeons Intermacs Analysis
AU - Cogswell, Rebecca
AU - Cantor, Ryan S.
AU - Vorovich, Esther
AU - Kilic, Arman
AU - Stehlik, Josef
AU - Cowger, Jennifer A.
AU - Habib, Robert H.
AU - Kirklin, James K.
AU - Pagani, Francis D.
AU - Atluri, Pavan
N1 - Funding Information:
The data for this research were provided by The Society of Thoracic Surgeons’ National Database Access and Publications Research Program.
Publisher Copyright:
© 2022 The Society of Thoracic Surgeons
PY - 2022/11
Y1 - 2022/11
N2 - Background: On June 3, 2021 Medtronic, Inc announced discontinuation of the HVAD left ventricular assist device. The purpose of this analysis was to provide summary data on surgical risks of HVAD to HeartMate 3 exchange and compare survival after HVAD to HeartMate 3 exchange to survival after primary HVAD implantation. Methods: Three cohorts within The Society of Thoracic Surgeons Intermacs database were identified: primary HVAD implant cohort (January 2017 to March 2021, n = 3797), HVAD to HeartMate 3 exchange cohort (December 2017 to March 2021, n = 45), and HVAD to HVAD exchange cohort (January 2017 to March 2021, n = 234). Mortality after HVAD to HeartMate 3 exchange was modeled and compared with the constant hazard phase for risk of mortality while on continued HVAD support. As a secondary analysis outcomes and survival were compared between patients who underwent HVAD to HeartMate 3 and HVAD to HVAD exchange. Results: HVAD to HeartMate 3 exchange was associated with significantly reduced survival compared with survival while remaining on HVAD support (6 months after exchange, 73.8% [70% confidence interval, 68.6-77.8] vs 79.0% [70% confidence interval, 78.3-79] for continued HVAD support). Compared with HVAD to HVAD exchange, survival was higher after replacement with HeartMate 3 (1 year: 85.9% [70% confidence interval, 79.5-90.5] vs 66.6% [70% confidence interval, 63.0-70.0], P = .009). Conclusions: Compared with continued support on HVAD, an exchange to HeartMate 3 was found to be associated with a significant increase in mortality. For patients who required pump exchange on HVAD support, exchange to HeartMate 3 demonstrated superior survival. Currently there is insufficient evidence to support elective exchange from an HVAD to HeartMate 3.
AB - Background: On June 3, 2021 Medtronic, Inc announced discontinuation of the HVAD left ventricular assist device. The purpose of this analysis was to provide summary data on surgical risks of HVAD to HeartMate 3 exchange and compare survival after HVAD to HeartMate 3 exchange to survival after primary HVAD implantation. Methods: Three cohorts within The Society of Thoracic Surgeons Intermacs database were identified: primary HVAD implant cohort (January 2017 to March 2021, n = 3797), HVAD to HeartMate 3 exchange cohort (December 2017 to March 2021, n = 45), and HVAD to HVAD exchange cohort (January 2017 to March 2021, n = 234). Mortality after HVAD to HeartMate 3 exchange was modeled and compared with the constant hazard phase for risk of mortality while on continued HVAD support. As a secondary analysis outcomes and survival were compared between patients who underwent HVAD to HeartMate 3 and HVAD to HVAD exchange. Results: HVAD to HeartMate 3 exchange was associated with significantly reduced survival compared with survival while remaining on HVAD support (6 months after exchange, 73.8% [70% confidence interval, 68.6-77.8] vs 79.0% [70% confidence interval, 78.3-79] for continued HVAD support). Compared with HVAD to HVAD exchange, survival was higher after replacement with HeartMate 3 (1 year: 85.9% [70% confidence interval, 79.5-90.5] vs 66.6% [70% confidence interval, 63.0-70.0], P = .009). Conclusions: Compared with continued support on HVAD, an exchange to HeartMate 3 was found to be associated with a significant increase in mortality. For patients who required pump exchange on HVAD support, exchange to HeartMate 3 demonstrated superior survival. Currently there is insufficient evidence to support elective exchange from an HVAD to HeartMate 3.
UR - http://www.scopus.com/inward/record.url?scp=85120611432&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85120611432&partnerID=8YFLogxK
U2 - 10.1016/j.athoracsur.2021.09.031
DO - 10.1016/j.athoracsur.2021.09.031
M3 - Article
C2 - 34678286
AN - SCOPUS:85120611432
SN - 0003-4975
VL - 114
SP - 1672
EP - 1678
JO - Annals of Thoracic Surgery
JF - Annals of Thoracic Surgery
IS - 5
ER -